Discovery and preclinical evaluation of BPB-101: a novel triple functional bispecific antibody targeting GARP-TGF-β complex/SLC, free TGF-β and PD-L1
BPB-101 is a potentially promising therapeutic candidate that may address unmet clinical needs in cancer immunotherapy, thus, BPB-101 warrants further clinical investigation.
Authors
- Wenqi Yu (ORCID: https://orcid.org/0000-0002-8376-3980)
- P F Li
- Hongjie Cheng
- Zhang Li (ORCID: https://orcid.org/0000-0002-0121-0187)
- Siyuan Ye (ORCID: https://orcid.org/0000-0003-0595-4682)
- Wenxin Xu (ORCID: https://orcid.org/0009-0008-0813-5969)
- Mengmeng Liu (ORCID: https://orcid.org/0000-0002-7072-3218)
- Mengshi Jiang
- Jiabing Wang
- Jieying Xu
- Lieming Ding
- Deyu Xu
- Huan Zheng
Institutions
- Betta Pharmaceuticals (China) (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-11-20
- DOI
- https://doi.org/10.3389/fimmu.2024.1479399
- Citations
- 2
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.57
Funders
- Betta Pharmaceuticals